Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Martin Edwards
AddedFeb 15, 2024
UpdatedMay 31, 2026
Martin Edwards

Martin Edwards

Board Member, KalVista Pharmaceuticals

Crunchbase

Martin Edwards's Career

KalVista Pharmaceuticals
KalVista Pharmaceuticals

Cambridge, MA, US

Board Member· Board
Morphic Therapeutic
Morphic Therapeutic

Waltham, MA, US

Board Member· Board
Logical Therapeutics
Logical Therapeutics

Waltham, MA, US

Board Member· Board
Tarsa Therapeutics
Tarsa Therapeutics

Philadelphia, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Martin Edwards's Career

KalVista Pharmaceuticals
KalVista Pharmaceuticals
Acquired$292.5M02004Cambridge, MA, US
Board Member· Board

Leadership at KalVista Pharmaceuticals

Brian J. G. PereiraBrian J. G. PereiraBoard Member
Edward P FeenerEdward P FeenerCo-Founder
Albert ChaAlbert ChaBoard Member
Robert HaighRobert HaighCo-Founder
T Andrew CrockettT Andrew CrockettCo-Founder
Lloyd P. AielloLloyd P. AielloCo-Founder

Similar to KalVista Pharmaceuticals

Rigel PharmaceuticalsRigel PharmaceuticalsSouth San Francisco, CA, USPharmaceuticalsest. 1996Rigel PharmaceuticalsSouth San Francisco, CA, US · est. 1996

Rigel Pharmaceuticals: A US-based biotech firm innovating small-molecule drugs for rare diseases and cancer.

Public · $192.5M155
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
AstraZenecaAstraZenecaCambridge, Cambridgeshire, GBPharmaceuticalsest. 1999AstraZenecaCambridge, Cambridgeshire, GB · est. 1999

AstraZeneca PLC: A British-Swedish firm specializing in research, manufacturing, and sales of pharmaceuticals.

Public · $3.8B83.5k
Morphic Therapeutic
Morphic Therapeutic
Public$510.5M1022015Waltham, MA, US
Board Member· Board

Leadership at Morphic Therapeutic

Norbert BischofbergerNorbert BischofbergerBoard Member
Amir NashatAmir NashatBoard Member
Praveen TipirneniPraveen TipirneniBoard Member
Susannah GraySusannah GrayBoard Member
Otello StampacchiaOtello StampacchiaBoard Member
Joseph P. SlatteryJoseph P. SlatteryBoard Member

Similar to Morphic Therapeutic

Pliant TherapeuticsPliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124
MorphoceuticalsMorphoceuticalsMarblehead, MA, USBiotechnologyest. 2020MorphoceuticalsMarblehead, MA, US · est. 2020

Morphoceuticals Inc.: Pioneering bioelectric solutions for limb regeneration in biotechnology.

Seed · $8M8
VeraMorphVeraMorphMansfield, MA, USPharmaceuticalsest. 2017VeraMorphMansfield, MA, US · est. 2017

VeraMorph: Innovating polymer-based oral dosage technology in pharmaceuticals since 2017.

Angel · $225k2
Logical Therapeutics
Logical Therapeutics
Public$79.4M302005Waltham, MA, US
Board Member· Board

Leadership at Logical Therapeutics

Bryant FongBryant FongBoard Member
Carolyn GreenCarolyn GreenFounder
Mitchell FinkMitchell FinkCEO
Paul SchmittPaul SchmittBoard Member
Dr Lutz B GiebelDr Lutz B GiebelBoard Member

Similar to Logical Therapeutics

VlstVlstSeattle, WA, USPharmaceuticalsVlstSeattle, WA, US

Viral Logic Systems Technology Corp., a US-based pharmaceutical company, specializes in inflammatory treatments.

Public · $55M30
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
ComplexaComplexaPittsburgh, PA, USTherapeuticsest. 2008ComplexaPittsburgh, PA, US · est. 2008

Complexa, Inc.: A biopharmaceutical firm innovating therapies for inflammatory and metabolic diseases.

Public · $86.9M7
Resolvyx PharmaceuticalsResolvyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2001Resolvyx PharmaceuticalsCambridge, MA, US · est. 2001

Resolvyx Pharmaceuticals: Developing lipid-based therapeutics for inflammatory diseases.

Seed · $20.7M30
Tarsa Therapeutics
Tarsa Therapeutics
Acquired$124.3M02009Philadelphia, PA, US
Board Member· Board

Leadership at Tarsa Therapeutics

Richard S. KollenderRichard S. KollenderBoard Member
Matt RiekeMatt RiekeBoard Member
Eric BednarskiEric BednarskiBoard Member
David BrandDavid BrandBoard Member
James GilliganJames GilliganCo-Founder
Jim TananbaumJim TananbaumBoard Member

Martin Edwards's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Martin Edwards

Ed UnkartEd UnkartBoard Member · KalVista PharmaceuticalsHoward B. RosenHoward B. RosenBoard Member · TalpheraMichael KauffmanMichael KauffmanBoard Member · Kezar Life SciencesVaughn KailianVaughn KailianBoard Member · Cephalon